---
document_datetime: 2025-11-23 14:31:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/osseor.html
document_name: osseor.html
version: success
processing_time: 0.1217382
conversion_datetime: 2025-12-28 12:28:38.608453
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Osseor

[RSS](/en/individual-human-medicine.xml/65536)

##### Withdrawn

This medicine's authorisation has been withdrawn

strontium ranelate

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Osseor](#news-on)
- [More information on Osseor](#more-information-on-osseor-460)
- [More information on Osseor](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 14 April 2020, the European Commission withdrew the marketing authorisation for Osseor (strontium ranelate) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Les Laboratoires Servier, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Osseor was granted marketing authorisation in the EU on 21 September 2004 for treatment of osteoporosis. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2009. It was then granted unlimited validity in 2014. The product had not been marketed in the EU since 2017.

The European Public Assessment Report (EPAR) for Osseor is updated to indicate that the marketing authorisation is no longer valid.

Osseor : EPAR - Summary for the public

English (EN) (639.48 KB - PDF)

**First published:** 04/12/2009

**Last updated:** 16/07/2014

[View](/en/documents/overview/osseor-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-369)

български (BG) (756.91 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/bg/documents/overview/osseor-epar-summary-public_bg.pdf)

español (ES) (664.71 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/es/documents/overview/osseor-epar-summary-public_es.pdf)

čeština (CS) (712.71 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/cs/documents/overview/osseor-epar-summary-public_cs.pdf)

dansk (DA) (638.69 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/da/documents/overview/osseor-epar-summary-public_da.pdf)

Deutsch (DE) (642.97 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/de/documents/overview/osseor-epar-summary-public_de.pdf)

eesti keel (ET) (638.5 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/et/documents/overview/osseor-epar-summary-public_et.pdf)

ελληνικά (EL) (759.01 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/el/documents/overview/osseor-epar-summary-public_el.pdf)

français (FR) (642.44 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/fr/documents/overview/osseor-epar-summary-public_fr.pdf)

hrvatski (HR) (660.67 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/hr/documents/overview/osseor-epar-summary-public_hr.pdf)

italiano (IT) (638.87 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/it/documents/overview/osseor-epar-summary-public_it.pdf)

latviešu valoda (LV) (1.32 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/lv/documents/overview/osseor-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (697.68 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/lt/documents/overview/osseor-epar-summary-public_lt.pdf)

magyar (HU) (708.21 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/hu/documents/overview/osseor-epar-summary-public_hu.pdf)

Malti (MT) (715.36 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/mt/documents/overview/osseor-epar-summary-public_mt.pdf)

Nederlands (NL) (639.2 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/nl/documents/overview/osseor-epar-summary-public_nl.pdf)

polski (PL) (734.75 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/pl/documents/overview/osseor-epar-summary-public_pl.pdf)

português (PT) (664.08 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/pt/documents/overview/osseor-epar-summary-public_pt.pdf)

română (RO) (663.01 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/ro/documents/overview/osseor-epar-summary-public_ro.pdf)

slovenčina (SK) (713.56 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/sk/documents/overview/osseor-epar-summary-public_sk.pdf)

slovenščina (SL) (727.28 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/sl/documents/overview/osseor-epar-summary-public_sl.pdf)

Suomi (FI) (639.21 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/fi/documents/overview/osseor-epar-summary-public_fi.pdf)

svenska (SV) (639.5 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

16/07/2014

[View](/sv/documents/overview/osseor-epar-summary-public_sv.pdf)

## Product information

Osseor : EPAR - Product Information

English (EN) (1.04 MB - PDF)

**First published:** 04/12/2009

**Last updated:** 07/12/2018

[View](/en/documents/product-information/osseor-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-476)

български (BG) (1.91 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/bg/documents/product-information/osseor-epar-product-information_bg.pdf)

español (ES) (1.03 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/es/documents/product-information/osseor-epar-product-information_es.pdf)

čeština (CS) (1.6 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/cs/documents/product-information/osseor-epar-product-information_cs.pdf)

dansk (DA) (1.11 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/da/documents/product-information/osseor-epar-product-information_da.pdf)

Deutsch (DE) (1.06 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/de/documents/product-information/osseor-epar-product-information_de.pdf)

eesti keel (ET) (968.4 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/et/documents/product-information/osseor-epar-product-information_et.pdf)

ελληνικά (EL) (2.11 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/el/documents/product-information/osseor-epar-product-information_el.pdf)

français (FR) (1.07 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/fr/documents/product-information/osseor-epar-product-information_fr.pdf)

hrvatski (HR) (1.1 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/hr/documents/product-information/osseor-epar-product-information_hr.pdf)

íslenska (IS) (1.06 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/is/documents/product-information/osseor-epar-product-information_is.pdf)

italiano (IT) (1.06 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/it/documents/product-information/osseor-epar-product-information_it.pdf)

latviešu valoda (LV) (1.78 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/lv/documents/product-information/osseor-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/lt/documents/product-information/osseor-epar-product-information_lt.pdf)

magyar (HU) (1.69 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/hu/documents/product-information/osseor-epar-product-information_hu.pdf)

Malti (MT) (1.79 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/mt/documents/product-information/osseor-epar-product-information_mt.pdf)

Nederlands (NL) (1.12 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/nl/documents/product-information/osseor-epar-product-information_nl.pdf)

norsk (NO) (1.12 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/no/documents/product-information/osseor-epar-product-information_no.pdf)

polski (PL) (1.71 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/pl/documents/product-information/osseor-epar-product-information_pl.pdf)

português (PT) (990.79 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/pt/documents/product-information/osseor-epar-product-information_pt.pdf)

română (RO) (1.04 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/ro/documents/product-information/osseor-epar-product-information_ro.pdf)

slovenčina (SK) (1.73 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/sk/documents/product-information/osseor-epar-product-information_sk.pdf)

slovenščina (SL) (1.59 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/sl/documents/product-information/osseor-epar-product-information_sl.pdf)

Suomi (FI) (1.1 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/fi/documents/product-information/osseor-epar-product-information_fi.pdf)

svenska (SV) (1.1 MB - PDF)

**First published:**

04/12/2009

**Last updated:**

07/12/2018

[View](/sv/documents/product-information/osseor-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** SW/0045 22/05/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Osseor : EPAR - All Authorised presentations

English (EN) (622.5 KB - PDF)

**First published:** 21/11/2005

**Last updated:** 21/11/2005

[View](/en/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-364)

български (BG) (631.65 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/bg/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_bg.pdf)

español (ES) (622.11 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/es/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_es.pdf)

čeština (CS) (663.13 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/cs/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (622.56 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/da/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (627.49 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/de/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (621.3 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/et/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (663.76 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/el/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_el.pdf)

français (FR) (622.66 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/fr/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (620.8 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/it/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (663.05 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/lv/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (642.87 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/lt/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (639.67 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/hu/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (662.9 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/mt/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (623.5 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/nl/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_nl.pdf)

polski (PL) (653.25 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/pl/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_pl.pdf)

português (PT) (624.39 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/pt/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_pt.pdf)

română (RO) (631.72 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/ro/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (653 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/sk/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (658.67 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/sl/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (622.44 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/fi/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (623.74 KB - PDF)

**First published:**

21/11/2005

**Last updated:**

21/11/2005

[View](/sv/documents/all-authorised-presentations/osseor-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Osseor Active substance strontium ranelate International non-proprietary name (INN) or common name strontium ranelate Therapeutic area (MeSH) Osteoporosis, Postmenopausal Anatomical therapeutic chemical (ATC) code M05BX03

### Pharmacotherapeutic group

Drugs for treatment of bone diseases

### Therapeutic indication

Treatment of severe osteoporosis in postmenopausal women at high risk for fracture to reduce the risk of vertebral and hip fractures.

Treatment of severe osteoporosis in adult men at increased risk of fracture.

The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks.

## Authorisation details

EMA product number EMEA/H/C/000561 Marketing authorisation holder

Les Laboratoires Servier

Les Laboratoires Servier

Marketing authorisation issued 20/09/2004 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Osseor : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (743.34 KB - PDF)

**First published:** 04/12/2009

**Last updated:** 07/12/2018

[View](/en/documents/procedural-steps-after/osseor-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Osseor Article-20 procedure: CHMP scientific conclusions and PRAC assessment report

Reference Number: EMA/112925/2014

English (EN) (1.49 MB - PDF)

**First published:** 16/07/2014

**Last updated:** 16/07/2014

[View](/en/documents/scientific-conclusion/osseor-article-20-procedure-chmp-scientific-conclusions-and-prac-assessment-report_en.pdf)

Osseor-H-C-561-PSUV-0037 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/222395/2014

English (EN) (626.2 KB - PDF)

**First published:** 16/07/2014

**Last updated:** 16/07/2014

[View](/en/documents/scientific-conclusion/osseor-h-c-561-psuv-0037-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Osseor-H-C-561-PSU-0031 : EPAR - Assessment Report - Periodic safety update report

Adopted

Reference Number: EMA/PRAC/136656/2013

English (EN) (2.75 MB - PDF)

**First published:** 02/08/2013

**Last updated:** 02/08/2013

[View](/en/documents/variation-report/osseor-h-c-561-psu-0031-epar-assessment-report-periodic-safety-update-report_en.pdf)

Osseor-H-C-561-PSU-0031 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/CHMP/257649/2013

English (EN) (694.44 KB - PDF)

**First published:** 02/08/2013

**Last updated:** 02/08/2013

[View](/en/documents/scientific-conclusion/osseor-h-c-561-psu-0031-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Osseor-H-C-561-II-0027 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/353622/2012

English (EN) (2.19 MB - PDF)

**First published:** 04/09/2012

**Last updated:** 04/09/2012

[View](/en/documents/variation-report/osseor-h-c-561-ii-0027-epar-assessment-report-variation_en.pdf)

Osseor-H-C-561-A20-0030 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/CHMP/261595/2012

English (EN) (683.97 KB - PDF)

**First published:** 04/09/2012

**Last updated:** 04/09/2012

[View](/en/documents/variation-report/osseor-h-c-561-a20-0030-epar-assessment-report-article-20_en.pdf)

CHMP post-authorisation summary of positive opinion for Osseor

Adopted

Reference Number: EMA/311245/2012

English (EN) (606.31 KB - PDF)

**First published:** 25/05/2012

**Last updated:** 25/05/2012

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-osseor_en.pdf)

## Initial marketing authorisation documents

Osseor : EPAR - Scientific Discussion

English (EN) (899.88 KB - PDF)

**First published:** 21/11/2005

**Last updated:** 21/11/2005

[View](/en/documents/scientific-discussion/osseor-epar-scientific-discussion_en.pdf)

Osseor : EPAR - Procedural steps taken before authorisation

English (EN) (649.44 KB - PDF)

**First published:** 21/11/2005

**Last updated:** 21/11/2005

[View](/en/documents/procedural-steps/osseor-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Osseor

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-may-2014) 23/05/2014

[European Medicines Agency recommends that Protelos/Osseor remain available but with further restrictions](/en/news/european-medicines-agency-recommends-protelos-osseor-remain-available-further-restrictions) 21/02/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-january-2014) 24/01/2014

[PRAC recommends suspending use of Protelos/Osseor](/en/news/prac-recommends-suspending-use-protelos-osseor) 10/01/2014

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 January 2014](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-january-2014) 10/01/2014

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2013) 26/04/2013

[Recommendation to restrict the use of Protelos / Osseor (strontium ranelate)](/en/news/recommendation-restrict-use-protelos-osseor-strontium-ranelate) 26/04/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2013) 12/04/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 May 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-may-2012) 25/05/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 March 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-march-2012) 16/03/2012

[European Medicines Agency confirms positive benefit-risk balance of Protelos / Osseor, but recommends new contraindications and revised warnings](/en/news/european-medicines-agency-confirms-positive-benefit-risk-balance-protelos-osseor-recommends-new-contraindications-revised-warnings) 16/03/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency starts review of Protelos / Osseor](/en/news/european-medicines-agency-starts-review-protelos-osseor) 20/10/2011

[European Medicines Agency recommends changes in the product information for Protelos / Osseor due to the risk of severe hypersensitivity reactions](/en/news/european-medicines-agency-recommends-changes-product-information-protelos-osseor-due-risk-severe-hypersensitivity-reactions) 16/11/2007

#### More information on Osseor

- [Protelos and Osseor: Article-20 procedure](/en/medicines/human/referrals/protelos-osseor)

Protelos and Osseor Article-20 procedure: CHMP scientific conclusions and PRAC assessment report

Adopted

Reference Number: EMA/112925/2014

English (EN) (950 KB - PDF)

**First published:** 28/02/2014

**Last updated:** 28/02/2014

[View](/en/documents/referral/protelos-and-osseor-article-20-procedure-chmp-scientific-conclusions-and-prac-assessment-report_en.pdf)

PRAC recommends restriction in the use of Protelos / Osseor: Questions and answers

Reference Number: EMA/220628/2013

English (EN) (73.99 KB - PDF)

**First published:** 12/04/2013

**Last updated:** 12/04/2013

[View](/en/documents/medicine-qa/prac-recommends-restriction-use-protelos-osseor-questions-and-answers_en.pdf)

Questions and answers on the review of Protelos and Osseor (strontium ranelate)

Reference Number: EMA/183047/2012

English (EN) (67.99 KB - PDF)

**First published:** 16/03/2012

**Last updated:** 16/03/2012

[View](/en/documents/medicine-qa/questions-and-answers-review-protelos-and-osseor-strontium-ranelate_en.pdf)

Protelos / Osseor: Product information as approved by the CHMP on 15 March 2012, pending endorsement by the European Commission

English (EN) (399.86 KB - PDF)

**First published:** 16/03/2012

**Last updated:** 16/03/2012

[View](/en/documents/other/protelos-osseor-product-information-approved-chmp-15-march-2012-pending-endorsement-european-commission_en.pdf)

#### More information on Osseor

- [Strontium ranelate - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/strontium-ranelate-0)
- [EMEA-000733-PIP02-12 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000733-pip02-12)
- [Osseor - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/osseor)

**This page was last updated on** 19/05/2020

## Share this page

[Back to top](#main-content)